The apparently conflicting functions of EZH2 in cancer may therefore simply reflect the antithetic roles that the protein plays at distinct stages of the disease: tumour suppressor during tumour‐initiation, and tumour‐promoter after cells transform and reprogramme their epigenome. This evidence concerns the gene EZH2 and cancer.